invest1 publisher
Hanmi and Chong Kun Dang added half of Korea's 97.1 billion won drug R&D increase
Thirty of Korea's most exposed drugmakers raised first-half R&D by about a fifth as next year's generic price cuts approach, and the two largest spenders in the group supplied most of the increase. Four smaller firms cut.
Publishers:en.sedaily.com
Reality
- Evidence62
- Adoption58
- Hype gap+16
- Incentives70
- Confidence58